CHARLES RIVER LABORATORIES (CRL) Stock Analyst Ratings
USA - NYSE:CRL - US1598641074 - Common Stock
168.05 USD
-2.83 (-1.66%)
168.05 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 72% to CRL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 192.74. This target is 14.69% above the current price.
CRL was analyzed by 23 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about CRL.
In the previous month the buy percentage consensus was at a similar level.
CRL was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-06 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-06 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-06 | Baird | Upgrade | Neutral -> Outperform |
| 2025-10-17 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-10-06 | William Blair | Upgrade | Market Perform -> Outperform |
| 2025-10-03 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-02 | Barclays | Upgrade | Equal-Weight -> Overweight |
| 2025-09-09 | Jefferies | Upgrade | Hold -> Buy |
| 2025-08-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-08-07 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-07 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-07-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-07-09 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-05-23 | Redburn Atlantic | Upgrade | Neutral -> Buy |
| 2025-05-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-08 | Baird | Maintains | Neutral -> Neutral |
| 2025-04-10 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-09 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-03-21 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2025-03-04 | Citigroup | Upgrade | Sell -> Neutral |
| 2025-02-20 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-20 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-02-20 | Baird | Maintains | Neutral -> Neutral |
| 2025-02-18 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-03 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-01-23 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-22 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-01-17 | UBS | Downgrade | Buy -> Neutral |
| 2025-01-14 | William Blair | Reiterate | Outperform -> Outperform |
CHARLES RIVER LABORATORIES / CRL FAQ
What is the price target for CRL stock?
23 analysts have analysed CRL and the average price target is 192.74 USD. This implies a price increase of 14.69% is expected in the next year compared to the current price of 168.05.
Can you provide the consensus rating for CHARLES RIVER LABORATORIES stock?
The consensus rating for CHARLES RIVER LABORATORIES (CRL) is 72.1739 / 100 . This indicates that analysts generally have a positive outlook on the stock.